Pharmion European Thalidomide Application For Multiple Myeloma Withdrawn; Resubmission Planned
Data from two ongoing trials are expected to fill out the resubmission. The withdrawal decision was not based on safety issues, Pharmion says.
Data from two ongoing trials are expected to fill out the resubmission. The withdrawal decision was not based on safety issues, Pharmion says.